Tag Archives: bone

OncoMed’s Wnt-targeted experimental cancer drugs and bone-related adverse events

OncoMed is a biotech company that is developing therapies directed at the Wnt and Notch signaling pathways.  Clinical studies with two products directed at the Wnt pathway (Vantictumab Рanti-Fzd-7, and Fzd-8 Fc) have been halted by the company while it explores findings of bone toxicity. Continue reading